Bioamber (BIOA) versus Cytec Industries (NYSE:CYT) Critical Contrast

Bioamber (NYSE: BIOA) and Cytec Industries (NYSE:CYT) are both companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, analyst recommendations, dividends, institutional ownership, valuation and risk.

Analyst Recommendations

How to Become a New Pot Stock Millionaire

This is a breakdown of current ratings for Bioamber and Cytec Industries, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Bioamber 0 1 1 0 2.50
Cytec Industries 0 0 0 0 N/A

Bioamber presently has a consensus target price of $1.38, indicating a potential upside of 4,029.13%. Given Bioamber’s higher probable upside, equities research analysts plainly believe Bioamber is more favorable than Cytec Industries.


This table compares Bioamber and Cytec Industries’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Bioamber -238.43% -48.72% -22.92%
Cytec Industries 11.96% 18.60% 8.55%

Institutional & Insider Ownership

28.7% of Bioamber shares are owned by institutional investors. 8.3% of Bioamber shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Earnings and Valuation

This table compares Bioamber and Cytec Industries’ gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Bioamber $8.27 million 0.52 -$22.47 million N/A N/A
Cytec Industries N/A N/A N/A N/A N/A

Cytec Industries has lower revenue, but higher earnings than Bioamber.


Bioamber beats Cytec Industries on 5 of the 8 factors compared between the two stocks.

About Bioamber

BioAmber Inc. (BioAmber), formerly DNP Green Technology, Inc., is an industrial biotechnology company, which produces sustainable chemicals. The Company’s technology platform combines industrial biotechnology and chemical catalysis to convert renewable feedstocks into sustainable chemicals that are replacements for petroleum-derived chemicals, which are used in a range of everyday products, including plastics, food additives and personal care products. Its geographical segments include Europe and North America. Its product pipeline includes the derivatives of bio-succinic acid, such as 1,4 Butanediol (1,4 BDO) and tetrahydrofuran (THF), and succinic acid-based polyesters, and C6 building block chemicals, such as adipic acid, caprolactam and hexamethylenediamine (HMDA). Its products are used in various applications, including polyurethanes, resins and coatings, de-icing and coolant solutions, fine chemicals, lubricants, carpets, engineering plastics and artificial leather products.

About Cytec Industries

Cytec Industries Inc. is a global specialty materials and chemicals company focused on developing, manufacturing and selling value-added products. The Company offers aerospace and industrial materials, mining and plastics industries. The Company operates through four segments: Aerospace Materials, Industrial Materials, In Process Separation, and Additive Technologies. The Aerospace Materials segment includes advanced composites, carbon fiber, and structural film adhesives. The Industrial Materials segment includes structural composite materials, which serve automotive, motorsports, recreation, tooling, and other structural materials markets and process materials, which serves aerospace, wind energy, and other process materials markets. The In Process Separation segment includes mining chemicals and phosphines. The Additive Technologies segment includes polymer additives, specialty additives, and formulated resins. The Company operates as a wholly owned subsidiary of Solvay.

Receive News & Ratings for Bioamber Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioamber and related companies with's FREE daily email newsletter.

Leave a Reply